NCT04356729

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Active, enrolled Phase 2 Last updated 29 June 2025

What this trial tests

Phase 2 trial testing Atezolizumab in Clinical Stage III Cutaneous Melanoma AJCC v8 in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 August 2020

Primary endpoint
1 June 2026

1 September 2026

Quick facts

Lead sponsor	Elizabeth Buchbinder, MD
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	6 August 2020
Primary completion	1 June 2026
Estimated completion	1 September 2026
Sites	3 locations across United States

Drugs / interventions tested

• Atezolizumab (atezolizumab) — full drug profile →
• Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

• Clinical Stage III Cutaneous Melanoma AJCC v8 — all drugs for Clinical Stage III Cutaneous Melanoma AJCC v8 →
• Stage IV Melanoma — all drugs for Stage IV Melanoma →
• Unresectable Stage III Cutaneous Melanoma — all drugs for Unresectable Stage III Cutaneous Melanoma →
• Unresectable Stage IV Cutaneous Melanoma — all drugs for Unresectable Stage IV Cutaneous Melanoma →

Sponsor

Elizabeth Buchbinder, MD

Who can join

18 and older, any sex, with Clinical Stage III Cutaneous Melanoma AJCC v8 or Stage IV Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma.

The names of the study drugs involved in this study are:

* Atezolizumab
* Bevacizumab

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Pre-metastatic niche: formation, characteristics and therapeutic implication.
   Wang Y, Jia J, Wang F, Fang Y, et al · · 2024 · cited 143× · PMID 39317708 · DOI 10.1038/s41392-024-01937-7
2. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications.
   Fang J, Lu Y, Zheng J, Jiang X, et al · · 2023 · cited 131× · PMID 37666809 · DOI 10.1038/s41419-023-06119-x
3. Melanoma Management: From Epidemiology to Treatment and Latest Advances.
   Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. · · 2022 · cited 98× · PMID 36230575 · DOI 10.3390/cancers14194652
4. Endothelial cells in tumor microenvironment: insights and perspectives.
   Leone P, Malerba E, Susca N, Favoino E, et al · · 2024 · cited 90× · PMID 38426109 · DOI 10.3389/fimmu.2024.1367875
5. BRAF Gene and Melanoma: Back to the Future.
   Ottaviano M, Giunta EF, Tortora M, Curvietto M, et al · · 2021 · cited 75× · PMID 33801689 · DOI 10.3390/ijms22073474
6. Role of macrophages in tumor progression and therapy (Review).
   Xu Y, Wang X, Liu L, Wang J, et al · · 2022 · cited 57× · PMID 35362544 · DOI 10.3892/ijo.2022.5347
7. The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors.
   Bu MT, Chandrasekhar P, Ding L, Hugo W. · · 2022 · cited 51× · PMID 35577211 · DOI 10.1016/j.pharmthera.2022.108211
8. Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism.
   Yang F, Lee G, Fan Y. · · 2024 · cited 45× · PMID 38580870 · DOI 10.1007/s10456-024-09913-z